Vote Scores

Home / Companies / Astria Therapeutics, Inc. / 21 Jan 2026

Meeting · year to 30 June 2026207 filers reporting

Astria Therapeutics, Inc.: meeting of 21 Jan 2026

Votes reported on Form N-PX, item by item

207 Form N-PX filers reported votes at the Astria Therapeutics, Inc. meeting of 21 Jan 2026. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

4 vote records from 4 filers. 0 of the 2 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

50.0% for0.0% against50.0% other0.0% against management4 filers100.0% for0.0% against0.0% against management665,067 reported shares
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on pay tied to a merger or sale

307 vote records from 204 filers. 26 of the 194 filers that marked the item either way voted against management. 10 filers reported this item without a management mark.

82.4% for11.3% against6.4% other13.4% against management204 filers92.8% for6.1% against1.1% other7.2% against management35,939,032 reported shares
3

EXTRAORDINARY TRANSACTIONSIssuer

EXTRAORDINARY TRANSACTIONS: management items

Management items in this category are shown together; filers word and number them differently.

116 vote records from 58 filers. 0 of the 58 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management58 filers100.0% for0.0% against0.0% against management6,313,404 reported shares, counted once per item in this group
4

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

140 vote records from 66 filers. 7 of the 66 filers that marked the item either way voted against management.

89.4% for9.1% against1.5% other10.6% against management66 filers99.4% for0.5% against0.1% other0.6% against management7,830,913 reported shares, counted once per item in this group

How the largest families voted

Family2. Merger pay
VanguardFor
BlackRock and iSharesFor
FidelityFor
DimensionalFor
State Street and SPDRFor
American CenturyAgainst *
InvescoFor
EquitableFor
Charles SchwabFor
Nuveen and TIAAAgainst *
ProShares and ProFundsFor
John Hancock and ManulifeFor
Morgan Stanley, Eaton Vance and CalvertFor
J.P. MorganFor
Goldman SachsFor
PGIM and PrudentialFor
Northern Trust and FlexSharesFor
SEIFor
T. Rowe PriceFor
Lincoln FinancialFor
VoyaAgainst *
Russell InvestmentsFor
NationwideFor
Victory CapitalFor
Brighthouse FundsFor
Guggenheim and RydexFor
BNY MellonFor
PrincipalFor
Pacific Life fundsFor
Global XFor
AllianceBernsteinAgainst *
DWSFor
VirtusFor
Neuberger BermanFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Astria Therapeutics, Inc. meeting?

207 Form N-PX filers reported votes at the meeting of 21 Jan 2026. On say-on-pay, 0 of 2 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Astria Therapeutics, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Astria Therapeutics, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Astria Therapeutics, Inc. with a meeting date within three days of 21 Jan 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.